Mostrar el registro sencillo del ítem

dc.contributor.authorRivero-Menendez, Olga 
dc.contributor.authorCuenca-Estrella, Manuel 
dc.contributor.authorAlastruey-Izquierdo, Ana 
dc.date.accessioned2020-11-27T08:50:42Z
dc.date.available2020-11-27T08:50:42Z
dc.date.issued2020-08-28
dc.identifier.citationJ Antimicrob Chemother . 2020 Dec 1;75(12):3582-3585es_ES
dc.identifier.urihttp://hdl.handle.net/20.500.12105/11453
dc.description.abstractTo evaluate the in vitro activity of olorofim, a new broad-spectrum antifungal with a novel mechanism of action, against a collection of 123 Spanish clinical isolates belonging to five Scedosporium species and Lomentospora prolificans. The activity of olorofim against Scedosporium apiospermum (n = 30), Scedosporium boydii (n = 30), Scedosporium ellipsoideum (n = 10), Scedosporium aurantiacum (n = 20), Scedosporium dehoogii (n = 3) and Lomentospora prolificans (n = 30) was compared with that of amphotericin B, voriconazole, isavuconazole and micafungin by performing EUCAST and CLSI reference methods for antifungal susceptibility testing. Amphotericin B and isavuconazole showed MICs ≥2 mg/L for all the species evaluated and voriconazole was moderately active (GM, MIC50 and MIC90 values ≤2 mg/L) against all of them except L. prolificans. Micafungin was effective against S. apiospermum complex strains, but exhibited elevated MECs for S. dehoogii and S. aurantiacum. Olorofim showed low MICs for all the Scedosporium strains tested (GM values were lower than 0.130 and 0.339 by the EUCAST method and the CLSI method, respectively, for all of the species), including those belonging to the MDR species L. prolificans, for which GM values were 0.115 and 0.225 mg/L by the EUCAST method and the CLSI method, respectively, while the GMs for the rest of the antifungals evaluated were higher than 3.732 mg/L using both methodologies. Olorofim displayed promising in vitro activity against the Scedosporium and L. prolificans strains tested, some of which have reduced susceptibility to the antifungals that are currently in use.es_ES
dc.description.sponsorshipThis work was supported by F2G Ltd (UK). O.R.-M. is supported by a fel-lowship from the Fondo de Investigacio ́ n Sanitaria (grant FI14CIII/00025). The funders had no role in the study design, data collection,analysis, decision to publish or preparation/content of the manuscript.es_ES
dc.language.isoenges_ES
dc.publisherBritish Society for Antimicrobial Chemotherapy (BSAC) es_ES
dc.type.hasVersionAMes_ES
dc.rights.urihttp://creativecommons.org/licenses/by-nc-sa/4.0/*
dc.subjectScedosporiumes_ES
dc.subjectLomentosporaes_ES
dc.subjectAntifungal activityes_ES
dc.subjectAntifungal resistancees_ES
dc.subjectIn vitro susceptibilityes_ES
dc.titleIn vitro activity of olorofim against clinical isolates of Scedosporium species and Lomentospora prolificans using EUCAST and CLSI methodologies.es_ES
dc.typejournal articlees_ES
dc.rights.licenseAtribución-NoComercial-CompartirIgual 4.0 Internacional*
dc.identifier.pubmedID32856079es_ES
dc.format.volume75es_ES
dc.format.number(12)es_ES
dc.format.page3582-3585es_ES
dc.identifier.doi10.1093/jac/dkaa351es_ES
dc.contributor.funderInstituto de Salud Carlos III 
dc.contributor.funderF2G (UK)
dc.description.peerreviewedSies_ES
dc.identifier.e-issn1460-2091
dc.relation.publisherversionhttps://doi.org/10.1093/jac/dkaa351es_ES
dc.identifier.journalThe Journal of antimicrobial chemotherapyes_ES
dc.repisalud.centroISCIII::Centro Nacional de Microbiologíaes_ES
dc.repisalud.institucionISCIIIes_ES
dc.relation.projectIDinfo:eu-repo/grantAgreement/ES/FI14CIII/00025es_ES
dc.rights.accessRightsopen accesses_ES


Ficheros en el ítem

Acceso Abierto
Thumbnail

Este ítem aparece en la(s) siguiente(s) colección(ones)

Mostrar el registro sencillo del ítem

Atribución-NoComercial-CompartirIgual 4.0 Internacional
Este Item está sujeto a una licencia Creative Commons: Atribución-NoComercial-CompartirIgual 4.0 Internacional